The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris - 05/09/11
Abstract |
Background: Pemphigus vulgaris is an autoimmune blistering disease for which the mainstay of treatment is systemic corticosteroids and immunosuppressants. This therapy had reduced the mortality of pemphigus; however, it is associated with significant morbidity. Objective: The objective of this study was to assess the group's experience with plasmapheresis in the treatment of pemphigus vulgaris and report on its utility. Methods: Seven patients with severe or resistant pemphigus vulgaris underwent a series of 5 plasma exchanges over an average of 8 days. Immunosuppressive drugs were administered immediately after plasmapheresis to prevent the “rebound” flare of disease that can occur after plasmapheresis. Results: Remission was induced in 4 patients, partial remission was induced in 2 patients, and 1 patient continues to have active disease. Conclusion: This study suggests that plasmapheresis is a useful intervention in patients with pemphigus vulgaris who are not responding to standard therapy or who require unacceptably high doses of steroids or immunosuppressants. (J Am Acad Dermatol 2000;43:1058-64.)
Le texte complet de cet article est disponible en PDF.Abbreviations : CR:, Dsg:, ICAb:, PR:, PV:
Plan
Reprint requests: Daniel Sauder, MD, Dermatology M-1, Sunnybrook Health Science Center, University of Toronto Clinic, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada. E-mail: Daniel.Sauder@Sunnybrook.on.ca. |
|
*Mr Turner is a medical student at Upstate Medical University, Syracuse. |
|
J Am Acad Dermatol 2000;43:1058-64. |
Vol 43 - N° 6
P. 1058-1064 - décembre 2000 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?